ACT Brief: APAC Inspection Findings, RBQM Key Risk Indicators, and Head and Neck Cancer Approval

0:00-1:47

In today’s ACT Brief, we examine why APAC inspection findings mirror those in the US and Europe, how key risk indicators should be read together, and how FDA granted accelerated approval to a subcutaneous antibody therapy for recurrent head and neck cancer.

Publisher

Applied Clinical Trials

Link

audioboom.com/posts/8974352

Published

November 9, 2026

Duration

2 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

AC

Applied Clinical Trials

@appliedclinicaltrials

#apacinspectionfindings #rbqmkeyrisk #neckcancerapproval #lifesciences

The Nile